• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应对多西他赛(泰索帝)的毒性反应。

Coping with toxicities of docetaxel (Taxotere).

作者信息

Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, Kaye S

机构信息

Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.

出版信息

Ann Oncol. 1993 Aug;4(7):610-1. doi: 10.1093/oxfordjournals.annonc.a058599.

DOI:10.1093/oxfordjournals.annonc.a058599
PMID:8103352
Abstract

BACKGROUND

In phase II studies of the EORTC-ECTG, acute hypersensitivity reaction, edema and skin toxicity were important side effects of docetaxel (TaxotereTM).

PATIENTS AND METHODS

Fifty patients with solid tumors were treated with docetaxel at the University Hospital of Antwerp. Of these, 28% developed an acute hypersensitivity reaction and 20% edema. Twelve and three hours before the next docetaxel administrations those with the acute hypersensitivity reaction were subsequently pretreated orally with 32 mg of methylprednisolone, 10 mg of cetirizine and 1 mg of ketotifen.

CONCLUSIONS

The acute hypersensitivity reaction could be completely blocked in all but in 1 of 14 patients, and this pretreatment schedule had an important prophylactic effect on edema formation. Skin toxicity was successfully treated with an ointment of glycerin and chlorhexidine.

摘要

背景

在欧洲癌症研究与治疗组织实体瘤协作组(EORTC-ECTG)的II期研究中,急性过敏反应、水肿和皮肤毒性是多西他赛(泰索帝TM)的重要副作用。

患者与方法

50例实体瘤患者在安特卫普大学医院接受多西他赛治疗。其中,28%出现急性过敏反应,20%出现水肿。在下次多西他赛给药前12小时和3小时,对出现急性过敏反应的患者随后口服32毫克甲泼尼龙、10毫克西替利嗪和1毫克酮替芬进行预处理。

结论

除14例患者中的1例之外,急性过敏反应在所有患者中均可被完全阻断,且这种预处理方案对水肿形成具有重要的预防作用。皮肤毒性通过甘油和氯己定软膏成功治愈。

相似文献

1
Coping with toxicities of docetaxel (Taxotere).应对多西他赛(泰索帝)的毒性反应。
Ann Oncol. 1993 Aug;4(7):610-1. doi: 10.1093/oxfordjournals.annonc.a058599.
2
Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions.在发生严重过敏反应的患者中,预防性使用酮替芬后成功再次使用紫杉烷类药物。
Ann Oncol. 2000 Jul;11(7):899. doi: 10.1023/a:1008366801690.
3
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.皮质类固醇显著延迟多西他赛诱导的液体潴留的发生:欧洲癌症研究与治疗组织乳腺癌研究药物分会一项随机研究的最终结果
J Clin Oncol. 1997 Sep;15(9):3149-55. doi: 10.1200/JCO.1997.15.9.3149.
4
Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.多西他赛(泰索帝)在对紫杉醇(泰素)过敏患者中的应用。
Anticancer Drugs. 2000 Aug;11(7):565-8. doi: 10.1097/00001813-200008000-00007.
5
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.多西他赛(泰索帝):一种用于治疗晚期头颈部鳞状细胞癌患者的活性药物。欧洲癌症研究与治疗组织早期临床试验组。
Ann Oncol. 1994 Jul;5(6):533-7. doi: 10.1093/oxfordjournals.annonc.a058908.
6
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG).多西他赛(泰索帝)对非小细胞肺癌有效:欧洲癌症研究与治疗组织早期临床试验组(ECTG)的一项II期试验。
Br J Cancer. 1994 Aug;70(2):384-7. doi: 10.1038/bjc.1994.311.
7
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.一项多西他赛(泰索帝)用于晚期乳腺癌二线化疗的II期试验。欧洲癌症研究与治疗组织早期临床试验组的一项研究。
Ann Oncol. 1994 Jul;5(6):527-32.
8
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.多西他赛(泰索帝)在既往接受过治疗的转移性乳腺癌女性患者中的活性和毒性。
Aust N Z J Med. 1997 Feb;27(1):40-4. doi: 10.1111/j.1445-5994.1997.tb00912.x.
9
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
J Clin Oncol. 1994 Jul;12(7):1458-67. doi: 10.1200/JCO.1994.12.7.1458.
10
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.多西他赛作为转移性乳腺癌初始化疗的II期和药理学研究。
J Clin Oncol. 1996 Jan;14(1):58-65. doi: 10.1200/JCO.1996.14.1.58.

引用本文的文献

1
Comprehensive assessment of lower limb edema and its association with quality of life among men with prostate cancer.前列腺癌男性下肢水肿的综合评估及其与生活质量的关联。
Support Care Cancer. 2025 Jun 16;33(7):586. doi: 10.1007/s00520-025-09613-4.
2
Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience.早期HER-2阳性乳腺癌中多西他赛化疗时地塞米松预处理方案的比较研究:一家安全网医院的经验
J Oncol Pharm Pract. 2025 Mar;31(2):236-244. doi: 10.1177/10781552241232692. Epub 2024 Feb 29.
3
Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer.
评估降低多西他赛输注前后前列腺癌和乳腺癌患者地塞米松预防剂量安全性的1期研究
Cancers (Basel). 2023 Mar 9;15(6):1691. doi: 10.3390/cancers15061691.
4
Characteristics of Developmental and Healing Process of Docetaxel-Induced Lower Limb Edema in Patients with Stage IV Breast Cancer: A Case Series.多西他赛致IV期乳腺癌患者下肢水肿的发展及愈合过程特征:病例系列
Palliat Med Rep. 2023 Feb 20;4(1):49-55. doi: 10.1089/pmr.2022.0059. eCollection 2023.
5
Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions.癌症治疗中的过敏反应:抗肿瘤治疗诱导的超敏反应。
Int J Mol Sci. 2023 Feb 15;24(4):3886. doi: 10.3390/ijms24043886.
6
Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.微管干扰药物:在卵巢上皮癌治疗中的现状与未来作用
Cancers (Basel). 2021 Dec 12;13(24):6239. doi: 10.3390/cancers13246239.
7
Trastuzumab-Coated Nanoparticles Loaded With Docetaxel for Breast Cancer Therapy.载有多西他赛的曲妥珠单抗包被纳米颗粒用于乳腺癌治疗。
Dose Response. 2019 Sep 4;17(3):1559325819872583. doi: 10.1177/1559325819872583. eCollection 2019 Jul-Sep.
8
Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.低剂量地塞米松预处理联合每周一次多西他赛的效果及药物不良反应评估。
Support Care Cancer. 2017 Feb;25(2):429-437. doi: 10.1007/s00520-016-3420-y. Epub 2016 Sep 30.
9
Dermatological adverse events with taxane chemotherapy.紫杉烷类化疗的皮肤不良事件。
Eur J Dermatol. 2016 Oct 1;26(5):427-443. doi: 10.1684/ejd.2016.2833.
10
Acute Respiratory Distress Syndrome after Treatment of Metastatic Prostate Cancer with Taxotere: A Case Report and Literature Review.多西他赛治疗转移性前列腺癌后发生急性呼吸窘迫综合征:1例报告及文献复习
Case Rep Urol. 2015;2015:198381. doi: 10.1155/2015/198381. Epub 2015 Aug 13.